199 related articles for article (PubMed ID: 12798712)
1. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
Giuntoli RL; Metzinger DS; DiMarco CS; Cha SS; Sloan JA; Keeney GL; Gostout BS
Gynecol Oncol; 2003 Jun; 89(3):460-9. PubMed ID: 12798712
[TBL] [Abstract][Full Text] [Related]
2. Lymph node dissection in uterine leiomyosarcomas: A matched-pair study.
Coronado PJ; Alonso-Espias M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Aniorte SM; Mitidieri M; Lambaudie E; Dubois N; Zapardiel I;
Gynecol Oncol; 2023 Jul; 174():28-33. PubMed ID: 37146437
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
Wang Z; Shi N; Naing A; Janku F; Subbiah V; Araujo DM; Patel SR; Ludwig JA; Ramondetta LM; Levenback CF; Ramirez PT; Piha-Paul SA; Hong D; Karp DD; Tsimberidou AM; Meric-Bernstam F; Fu S
Cancer Med; 2016 Dec; 5(12):3437-3444. PubMed ID: 27882721
[TBL] [Abstract][Full Text] [Related]
4. Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma.
Gracia M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Cusine-Lopez L; Novak Z; Dallaku K; Zapardiel I;
Int J Gynaecol Obstet; 2023 Dec; 163(3):868-874. PubMed ID: 37485666
[TBL] [Abstract][Full Text] [Related]
5. Recurrent broad ligament leiomyosarcoma with pancreatic and thigh metastasis: a case report.
Tian X; Yan X; Wu J; Song H; Shen Z
BMC Surg; 2020 Jun; 20(1):143. PubMed ID: 32600468
[TBL] [Abstract][Full Text] [Related]
6. Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy.
Ziebarth AJ; Felder MA; Harter J; Connor JP
Cancer Immunol Immunother; 2012 Jul; 61(7):1149-53. PubMed ID: 22562378
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.
Hemming ML; Fan C; Raut CP; Demetri GD; Armstrong SA; Sicinska E; George S
Mol Cancer Res; 2020 Sep; 18(9):1302-1314. PubMed ID: 32518213
[TBL] [Abstract][Full Text] [Related]
8. A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases.
Chapel DB; Sharma A; Lastra RR; Maccio L; Bragantini E; Zannoni GF; George S; Quade BJ; Parra-Herran C; Nucci MR
Mod Pathol; 2022 Jun; 35(6):794-807. PubMed ID: 35121810
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous Leiomyosarcoma: An Aggressive Malignancy Portending a Significant Risk of Metastasis and Death.
Bresler SC; Gosnell HL; Ko JS; Angeles CV; Ronen S; Billings SD; Patel RM
Am J Surg Pathol; 2023 Dec; 47(12):1417-1424. PubMed ID: 37727934
[TBL] [Abstract][Full Text] [Related]
10. Bone Metastases in Patients with Leiomyosarcoma: A Retrospective Analysis of Survival and Surgical Management.
LiBrizzi CL; Vankara A; Meyer CF; Levin AS; Morris CD
Sarcoma; 2022; 2022():6806932. PubMed ID: 35570847
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of mitotic count in leiomyosarcoma: A comprehensive monocentric retrospective study.
Grimaudo MS; Renne SL; Colombo P; Giordano L; Gennaro N; Laffi A; Cariboni U; Cananzi FCM; Ruspi L; Santoro A; Bertuzzi AF
Hum Pathol; 2024 Jan; 143():17-23. PubMed ID: 38000682
[TBL] [Abstract][Full Text] [Related]
12. Ovarian Leiomyosarcoma as Incidentaloma during Postbariatric Abdominoplasty Surgical Procedure.
Mazzarella F; Brunelli D; Foletto M; Bassetto F; Vindigni V
Plast Reconstr Surg Glob Open; 2024 Jan; 12(1):e5536. PubMed ID: 38264446
[TBL] [Abstract][Full Text] [Related]
13. The Future of Targeted Therapy for Leiomyosarcoma.
Denu RA; Dann AM; Keung EZ; Nakazawa MS; Nassif Haddad EF
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473300
[TBL] [Abstract][Full Text] [Related]
14. Leiomyosarcoma of the uterine cervix associated with pregnancy: A case report and review of literature.
Whitcombe DD; Valente PT; Acosta OM; Kost ER
Gynecol Oncol Rep; 2016 Aug; 17():45-8. PubMed ID: 27355001
[TBL] [Abstract][Full Text] [Related]
15. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
Mahdavi A; Monk BJ; Ragazzo J; Hunter MI; Lentz SE; Vasilev SA; Tewari KS
Int J Gynecol Cancer; 2009 Aug; 19(6):1080-4. PubMed ID: 19820372
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).
Reed NS; Mangioni C; Malmström H; Scarfone G; Poveda A; Pecorelli S; Tateo S; Franchi M; Jobsen JJ; Coens C; Teodorovic I; Vergote I; Vermorken JB;
Eur J Cancer; 2008 Apr; 44(6):808-18. PubMed ID: 18378136
[TBL] [Abstract][Full Text] [Related]
17. Uterine sarcomas: a review.
D'Angelo E; Prat J
Gynecol Oncol; 2010 Jan; 116(1):131-9. PubMed ID: 19853898
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.
Kapp DS; Shin JY; Chan JK
Cancer; 2008 Feb; 112(4):820-30. PubMed ID: 18189292
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
Hensley ML; Ishill N; Soslow R; Larkin J; Abu-Rustum N; Sabbatini P; Konner J; Tew W; Spriggs D; Aghajanian CA
Gynecol Oncol; 2009 Mar; 112(3):563-7. PubMed ID: 19135708
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
